Chemotherapy and chemoembolization of patients with oncopathology as a risk factor for the development of myocardial dysfunction
Kubekova S. Zagorulya N. Ryb Y. Malayev N. Abdilda A.
2023National Scientific Medical Center
Journal of Clinical Medicine of Kazakhstan
2023#20Issue 24 - 8 pp.
Considering the aging of the population, the combination of cardiovascular diseases with oncopathology is gaining more relevance. Liver cancer occupies the 6th place in the structure of the incidence of neoplasms and the 3rd place in mortality from all oncological diseases. One of the main methods of treating patients with liver cancer is chemotherapy and chemoembolization, which significantly affect the myocardium, developing cardiotoxicity. Myocardial damage is reflected in the development of heart failure, which subsequently is the main cause of death in cancer patients.
cardiotoxicity , chemoembolization , heart failure , liver cancer , treatment
Text of the article Перейти на текст статьи
Department of Cardiology, Astana Medical University, Astana, Kazakhstan
Department of Internal Medicine with a Course of Gastroenterology, Endocrinology and Pulmonology, Astana Medical University, Astana, Kazakhstan
Department of General and Thoracic Surgery, National Scientific Medical Center, Astana, Kazakhstan
Department of Cardiology
Department of Internal Medicine with a Course of Gastroenterology
Department of General and Thoracic Surgery
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026